Aim of the working group: Theaim of the working
group is to improve the symptomatic treatment of Huntington`s disease
patients and to establish treatments for HD with studies that fullfil
the criteria of fact based medicine. Valuable data of symptomatic
treatment are important not only to improve patient care but also to
standardized the treatment. This standardisation will facilitate
neuroprotective treatment trials, because it will reduce variability of
the possible outcome measurements.
In the first steps the WG will conduct open label studies and
screen epidemiological data from REGISTRY to get an overview in the
used medication in HD care and to get an overview in the effects
of compounds for specific indication lile irritability,
hyperkinesia, bradykinesia and apathy .
In the following steps the WG will conduct controled trials in
order to establish the therapies, that are identified by the first
Besides medication therapie the WG will look on cotherapies like phyisiotherapy and speech therapy.